✓ No active regulatory warningsFDA MedWatch, EMA EudraVigilance, WHO VigiBase, WADA Prohibited List · 2026-05-29
📰Read the full Carboxymethylcellulose evidence review on GMJ News →Complete clinical article, references and updates on news.gmj.ge. This page is the structured safety summary.⚠ Patient concerned about CMC after reading 'gut inflammation' headlines — explain rodent vs human dose context [1]
⚠ Practitioner recommending CMC avoidance — would eliminate most tablet supplements; not evidence-based [1]
ℹ️ Not obtained from food. Not applicable — this is an inert capsule/excipient material, not a nutrient obtained from food.
🔬 Lab interpreter
ℹ️ No validated blood test. There is no established laboratory test to assess status or guide dosing for this ingredient. Clinical response and symptoms are the practical guide.
⚕ For professionals — confirm ranges against your local laboratory.
Clinical verdict
CMC is one of the most ubiquitous supplement excipients (>40% of tablets). JECFA 'ADI not specified,' FDA GRAS since 1961. The 2015 rodent gut inflammation study generated concern but used non-physiological doses in immunocompromised mice — no human confirmation. Avoiding CMC is impractical and not evidence-based. Croscarmellose sodium (cross-linked CMC) is the tablet disintegrant form [1].
1 How much do I need?
👤 Adults: Specific dosage data under clinical review
👴 Elderly: Specific dosage data under clinical review
🤰 Pregnancy: See guidance
Safe [1].
👦 Pediatric: See guidance
Safe. Present in children's supplements and food [1].
🏃 Athletes: Standard dose
⚖️ Obesity: Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
🩺 Renal: Consult specialist
Dose adjustment may be needed in renal impairment.
🌱 Vegan: Standard dose
How to take
🍽 Timing: N/A [1].
💊 With food: N/A [1].
🚫 Avoid: Avoidance not recommended based on current evidence [1].
2 Which form?
| Form | Bioavailability | Vegan | Cost |
|---|---|---|---|
| ['CMC in tablets (binder/disintegrant)', 'excipient', "0.5–5% of tablet weight. Listed in Other Ingredients as 'cellulose gum,' 'carboxymethylcellulose,' or 'croscarmellose sodium' (cross-linked form) [1]."] | Standard | Check label | |
| ['CMC in liquid supplements', 'thickener', 'Creates viscosity in syrups and suspensions [1].'] | Standard | Check label | |
| ['CMC in food products', 'food additive', 'Ice cream, sauces, dressings, bakery products [1].'] | Standard | Check label |
3 Common questions
Should I avoid CMC after the gut inflammation study? ▼
The 2015 Chassaing study used germ-free and genetically susceptible mice at doses far above human exposure. No human study has confirmed gut barrier disruption from dietary CMC. JECFA, FDA, and EFSA have not changed CMC's safety status. Avoiding CMC would eliminate >40% of supplement tablets and countless foods — a disproportionate response to one rodent study [1].
What is croscarmellose sodium? ▼
It is the cross-linked form of CMC, used specifically as a tablet disintegrant (helps tablets break apart in the stomach). Same safety profile as CMC [1].
4 Clinical evidence
Strong
Safety: JECFA ADI 'not specified.' FDA GRAS since 1961. >60 years of use without identified human safety concerns at dietary levels [1]. HIGH
Moderate
2015 rodent controversy: Chassaing et al. (Nature, 2015) found CMC and polysorbate-80 at 1% of drinking water promoted intestinal inflammation and metabolic syndrome in mice. This generated headlines but the doses were far above human dietary exposure, the model used germ-free and IL-10 knockout mice (not normal immunity), and NO human studies have confirmed the findings [1]. MODERATE
Insufficient
Human gut barrier effects: no clinical trials. IBD association: ecological, not causal. Metabolic syndrome from CMC: rodent data only [1]. LOW
5 Safety, toxicity & adverse events
Relative
⚠ Inert thickening/bulking excipient — no pharmacological contraindications at use levels
⚠ High-volume bulk-laxative forms need adequate fluid
⚠ Research on dietary-emulsifier effects on the gut microbiome is ongoing
6 Interactions
Drug interactions
7 Regulatory
FDA: GRAS since 1961 [1].
JECFA: ADI 'not specified' [1].
EFSA: E466. Re-evaluated 2018; safety confirmed [1].
8 Cite this page
Vancouver: Pkhakadze G. Carboxymethylcellulose — safety profile [Internet]. Tbilisi: PHIG; 2026 [cited 2026 Aug 15]. Available from: https://supplement.ge/ingredients/carboxymethylcellulose/
APA 7th: Pkhakadze, G. (2026). Carboxymethylcellulose — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/carboxymethylcellulose/
📋 Editorial information
Author: Prof. G. Pkhakadze, MD, MPH, PhD
Institution: Public Health Institute of Georgia (PHIG)
Affiliation: David Tvildiani Medical University (DTMU)
First published: January 2026
Last reviewed: 2026-05-29
Next review: February 2027
References: 3 cited sources
COI: SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
Process: Systematic literature review
📄 License & reuse
Published under Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt for any purpose with attribution.
Pkhakadze G. "Carboxymethylcellulose — Safety Profile." SupplementIndex, PHIG, 2026. https://supplement.ge/ingredients/carboxymethylcellulose/ CC BY 4.0.
GP
Prof. G. Pkhakadze, MD, MPH, PhD
Professor of Public Health · Head of Department, DTMU
Editor-in-Chief, Georgian Medical Journal (ISSN 3088-4322)
Chair, Public Health Institute of Georgia · UEMS Public Health Section
Educational and public health purposes. CC BY 4.0. Consult your healthcare provider before starting any supplement. Corrections: info@accreditation.ge. Publisher: PHIG